These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24827739)

  • 1. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.
    Jiang H; Clise-Dwyer K; Ruisaard KE; Fan X; Tian W; Gumin J; Lamfers ML; Kleijn A; Lang FF; Yung WK; Vence LM; Gomez-Manzano C; Fueyo J
    PLoS One; 2014; 9(5):e97407. PubMed ID: 24827739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
    Jiang H; Rivera-Molina Y; Gomez-Manzano C; Clise-Dwyer K; Bover L; Vence LM; Yuan Y; Lang FF; Toniatti C; Hossain MB; Fueyo J
    Cancer Res; 2017 Jul; 77(14):3894-3907. PubMed ID: 28566332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
    Phillips LM; Li S; Gumin J; Daou M; Ledbetter D; Yang J; Singh S; Parker Kerrigan BC; Hossain A; Yuan Y; Gomez-Manzano C; Fueyo J; Lang FF
    Neuro Oncol; 2021 Nov; 23(11):1911-1921. PubMed ID: 34059921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection.
    Grekova SP; Raykov Z; Zawatzky R; Rommelaere J; Koch U
    Cancer Gene Ther; 2012 Jul; 19(7):468-75. PubMed ID: 22539062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.
    Kleijn A; Kloezeman J; Treffers-Westerlaken E; Fulci G; Leenstra S; Dirven C; Debets R; Lamfers M
    PLoS One; 2014; 9(5):e97495. PubMed ID: 24866126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.
    Martínez-Vélez N; Garcia-Moure M; Marigil M; González-Huarriz M; Puigdelloses M; Gallego Pérez-Larraya J; Zalacaín M; Marrodán L; Varela-Guruceaga M; Laspidea V; Aristu JJ; Ramos LI; Tejada-Solís S; Díez-Valle R; Jones C; Mackay A; Martínez-Climent JA; García-Barchino MJ; Raabe E; Monje M; Becher OJ; Junier MP; El-Habr EA; Chneiweiss H; Aldave G; Jiang H; Fueyo J; Patiño-García A; Gomez-Manzano C; Alonso MM
    Nat Commun; 2019 May; 10(1):2235. PubMed ID: 31138805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.
    Tähtinen S; Grönberg-Vähä-Koskela S; Lumen D; Merisalo-Soikkeli M; Siurala M; Airaksinen AJ; Vähä-Koskela M; Hemminki A
    Cancer Immunol Res; 2015 Aug; 3(8):915-25. PubMed ID: 25977260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET.
    Garcia-Moure M; Gonzalez-Huarriz M; Labiano S; Guruceaga E; Bandres E; Zalacain M; Marrodan L; de Andrea C; Villalba M; Martinez-Velez N; Laspidea V; Puigdelloses M; Gallego Perez-Larraya J; Iñigo-Marco I; Stripecke R; Chan JA; Raabe EH; Kool M; Gomez-Manzano C; Fueyo J; Patiño-García A; Alonso MM
    Clin Cancer Res; 2021 Mar; 27(6):1807-1820. PubMed ID: 33376098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice.
    Shin DH; Jiang H; Gillard AG; Kim D; Fan X; Singh SK; Nguyen TT; Sohoni SS; Lopez-Rivas AR; Parthasarathy A; Ene CI; Gumin J; Lang FF; Alonso MM; Gomez-Manzano C; Fueyo J
    Mol Ther; 2024 Mar; 32(3):722-733. PubMed ID: 38311852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity.
    Jiang H; Shin DH; Yi Y; Fan X; Gumin J; He J; Gillard AG; Lang FF; Gomez-Manzano C; Fueyo J
    Cancer Res Commun; 2023 Jun; 3(6):1118-1131. PubMed ID: 37379361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
    Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
    Chen D; Huang L; Zhou H; Zhang Y
    Front Immunol; 2021; 12():615089. PubMed ID: 33717103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site.
    Lopes A; Feola S; Ligot S; Fusciello M; Vandermeulen G; Préat V; Cerullo V
    J Immunother Cancer; 2019 Jul; 7(1):174. PubMed ID: 31291991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical Role of Autophagy in the Processing of Adenovirus Capsid-Incorporated Cancer-Specific Antigens.
    Klein SR; Jiang H; Hossain MB; Fan X; Gumin J; Dong A; Alonso MM; Gomez-Manzano C; Fueyo J
    PLoS One; 2016; 11(4):e0153814. PubMed ID: 27093696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway.
    Fueyo J; Alemany R; Gomez-Manzano C; Fuller GN; Khan A; Conrad CA; Liu TJ; Jiang H; Lemoine MG; Suzuki K; Sawaya R; Curiel DT; Yung WK; Lang FF
    J Natl Cancer Inst; 2003 May; 95(9):652-60. PubMed ID: 12734316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma.
    de Jonge J; Berghauser Pont LM; Idema S; Kloezeman JJ; Noske D; Dirven CM; Lamfers ML
    J Gene Med; 2013; 15(3-4):134-41. PubMed ID: 23606319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
    Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
    Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.
    Koks CA; Garg AD; Ehrhardt M; Riva M; Vandenberk L; Boon L; De Vleeschouwer S; Agostinis P; Graf N; Van Gool SW
    Int J Cancer; 2015 Mar; 136(5):E313-25. PubMed ID: 25208916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory.
    Rivera-Molina Y; Jiang H; Fueyo J; Nguyen T; Shin DH; Youssef G; Fan X; Gumin J; Alonso MM; Phadnis S; Lang FF; Gomez-Manzano C
    Neurooncol Adv; 2019; 1(1):vdz009. PubMed ID: 31608328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.
    Jiang H; Shin DH; Nguyen TT; Fueyo J; Fan X; Henry V; Carrillo CC; Yi Y; Alonso MM; Collier TL; Yuan Y; Lang FF; Gomez-Manzano C
    Clin Cancer Res; 2019 Nov; 25(22):6801-6814. PubMed ID: 31455679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.